<DOC>
	<DOCNO>NCT01787006</DOCNO>
	<brief_summary>Esophageal cancer highly aggressive tumor . Treatment option various range chemotherapy radiotherapy several surgical technique . Nevertheless , overall survival rate disease remain poor . During last year combination cetuximab standard chemotherapy radiotherapy mainly investigate clinical trial focus colorectal and/or head neck cancer . The result obtain thesis study encourage lead initiation active clinical research esophageal cancer patient antibody inhibition EGFR . The first data indication encourage show cetuximab safely add chemoradiation esophageal cancer patient first hint efficacy . Based experience cetuximab colorectal cancer combination radiotherapy head neck cancer , aim present study evaluate feasibility combine treatment cetuximab continuous infusional 5-FU , cisplatin radiotherapy patient esophageal cancer ass overall survival rate increase addition EGFR-targeted therapy .</brief_summary>
	<brief_title>Definitive Radiochemotherapy Plus/Minus Cetuximab Unresectable Locally Advanced Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Dated sign write informed consent Male female patient 18 year 75 year ; patient &gt; 75 year karnofsky performance status ≥ 80 . Histologically proven squamous cell carcinoma adenocarcinoma esophagus curatively resectable . Resectability define surgeon radiochemotherapy . The tumor consider unresectable due Tstage , Nstage , performance status , nutritional status , comorbidity ( pulmonal function , ) , tumor location upper third reason Karnofsky Performance Status ≥ 70 Women childbearing potential must negative pregnancy test Adequate cardial , pulmonal ear function Adequate bone marrow function : leukocytes ≥ 3.0 x 10^9/L neutrophile ≥ 1.5 x 10^9/L thrombocyte ≥ 100 x 10^9/L hemoglobin ≥ 10.0 g/dl Adequate liver function : bilirubin ≤ 2.0 mg/dl SGOT , SGPT , AP , gammaGT ≤ 3 x ULN Adequate kidney function : serum creatinine ≤ 1.5 mg/dl creatinine clearance ≥ 50 ml/min accord CockcroftGault Formula know allergy chimeric antibody effective contraception male female patient risk conception distant metastasis previous treatment esophageal cancer previous therapy monoclonal antibody / EGFRtargeted therapy previous second malignancy exception history previous curatively treat basal cell carcinoma skin preinvasive cervix carcinoma serious concomitant disease medical condition FEV1 &lt; 1.1 clinically relevant coronary artery disease know myocardial infarction within last 12 month ventricular ejection fraction ( LVEF ) normal every active dermatological condition &gt; grade 1 contraindication receive cisplatin , 5FU cetuximab concurrent treatment experimental drug participation another clinical trial within 30 day study start patient pregnant breast feed know drug abuse , medication abuse , alcohol abuse social situation limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>non resectable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>radiation</keyword>
</DOC>